Previous 10 | Next 10 |
Marinus Pharmaceuticals (NASDAQ:MRNS): GAAP EPS of -$0.53 beats by $0.12. Revenue of $10.11M beats by $4.95M. Press Release For further details see: Marinus Pharmaceuticals EPS beats by $0.12, beats on revenue
European Medicines Agency has accepted the Marketing Authorization Application for ganaxolone in CDKL5 deficiency disorder for review under accelerated assessment European Commission granted orphan drug designation to ganaxolone in tuberous sclerosis complex; Phase 3 TrustTSC prog...
Marinus Pharmaceuticals (NASDAQ:MRNS) is scheduled to announce Q3 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is -$0.65 (-27.5% Y/Y) and the consensus Revenue Estimate is $5.16M (+2935.3% Y/Y). Over the last 3 months, EPS estimates have seen 4 upw...
ADT,AGEN,AGTC,ALLT,APRN,AUD,OTCPK:BAYZF,BHVN,BNTX,BSY,CAH,CANO,CCO,CEVA,CNCE,CORR,DCTH,DHI,DRNA,EBIX,ECOM,EGRX,EPZM,EXK,FOLD,GILT,GLNG,GOL,HAE,HAIN,HGV,HUYA,IGT,IIVI,INSW,ISEE,ITCI,KNDI,KPLT,MIDD,MLCO,MNTV,MRNS,MRSN,MSGE,OTCPK:NSANY,NSPR,NUWE,OCGN,OESX,OSG,OWL,PLTR,PRPL,PRTY,QTNT,SATS,SEAS,SE...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced plans to release financial results for the third quarter ended September 30, 2021 before the market opens o...
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has joined forces with the Loulou Foundation , a private foundation dedicated to advancing research on t...
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will be presenting an overview and update of its pipeline and commercial plans across its programs in CDKL5 deficiency disorder...
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host a virtual R&D event for investors and analysts on Tuesday, October 5, 2021, from 9:00 a.m. to 12:00 p.m. Eastern ...
Six-month priority review granted with PDUFA target action date set for March 20, 2022 FDA indicated that it is not currently planning to hold an advisory committee meeting for the application NDA filing acceptance enables opportunity to draw $...
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has grant...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...